63rd ASH Annual Meeting & Exposition

Glycostem to participant the 63rd ASH Annual Meeting & Exposition virtually to present abstract online, about Clinical data of the first two acute myeloid leukemia patients enrolled in the phase I/IIa WiNK clinical trial.

Title: Allogeneic, CD34+, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease

Session Date/Time:  11th December 11, 2021 5:30 PM - 7:30 PM EST

Next Generation Cell & Gene Therapy Conference

Glycostem Chief Development Officer Volker Huppert to present at Next Generation Cell & Gene Therapy Conference about Scaling NK Manufacturing on 8th Nov.

8th Drug Discovery Strategic Summit

Glycostem to attend 8th European Drug Discovery Strategic Summit in Amsterdam, Netherlands on 4th & 5th November 2021. 

Glycostem to present at Cell UK 2021

Glycostem Chief Development Officer Volker Huppert to present 29th Oct at Cell UK 2021 organized by Oxford Global Conferences, to give a keynote speech about manufacturing scaling of CAR-NK product. This in-person event will also be streamed online.

Cord Blood Connect 2021

Glycostem to present at the 2021 virtual Cord Blood Connect international congress on 30th September 2021.

Session Topic:            Perinatal Tissues as Source Material for Novel Therapies
Session Date/Time:    30th September 2021  -  10:05 - 10:55 AM EDT / 16:05 – 16:55 PM CET

Advanced Therapies Connect

Glycostem to present virtually at the Advanced Therapies Connect  on 28-29th of September, 2021.